Background At the end of 2021, the European Medicines Agency (EMA) expanded its
approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the …

Abstract The Coronavirus disease‐2019 (COVID‐19) pandemic continues, and the death toll
continues to surge. This meta‐analysis aimed to determine the efficacy of anakinra on …

Introduction Severe COVID-19 cases have a detrimental hyper-inflammatory host response
and different cytokine-blocking biologic agents were explored to improve outcomes …

Objective We aimed to investigate whether anakinra, an interleukin-1receptor inhibitor,
could improve outcome in moderate COVID-19 patients. Methods In this controlled, open …

Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ …

This study aims to assess anakinra's safety and efficacy for treating severe coronavirus
disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 …

The role of immunomodulatory agents in the treatment of hospitalized patients with COVID-
19 has been of increasing interest. Anakinra, an interleukin-1 inhibitor, has been shown to …

Importance COVID-19 pneumonia is often associated with hyperinflammation. The efficacy
and safety of anakinra in treating patients with severe COVID-19 pneumonia and …

Objectives Acute respiratory distress syndrome and cytokine release syndrome are the
major complications of coronavirus disease 2019 (COVID-19) associated with increased …

Background In COVID-19, severe disease course such as need of intensive care unit (ICU)
as well as development of mortality is mainly due to cytokine storm. In this study, we aimed …